Protective Effects of Flavonoids as Potential Pharmacological Agents in Experimental Rat Models

Flavonoids, a diverse group of polyphenolic compounds widely distributed in plants, have attracted attention for their broad spectrum of biological activities and therapeutic potential. Numerous studies in experimental rat models have demonstrated that flavonoids exert protective effects against oxidative stress, inflammation, apoptosis, and tissue injury across various organ systems. Their mechanisms of action include scavenging reactive oxygen species, modulation of signaling pathways such as NF-κB, MAPK, and NRF2, as well as regulation of cytokine production and mitochondrial function. In models of cardiovascular, hepatic, renal, and neurodegenerative diseases, flavonoid administration has been shown to restore biochemical balance, reduce histopathological damage, and improve functional outcomes. However, their in vivo efficacy is strictly governed by a complex ADME cascade. Intestinal absorption is gated by enzymatic pathways like lactase phlorizin hydrolase (LPH) and sodium-dependent glucose transporter 1 (SGLT1), while metabolic fate is dominated by rapid Phase II conjugation, resulting in systemic profiles composed primarily of metabolites rather than parent aglycones. Furthermore, recent evidence in specialized rodent models, such as Late-Onset Depression (LOD), underscores the capacity of specific flavonoids like luteolin to cross the blood-brain barrier and actively reprogram hippocampal glycerophospholipid metabolism to mitigate neuroinflammation. This chapter provides a comprehensive overview of experimental findings from rat models, elucidating the biochemical and molecular mechanisms underlying the protective effects of flavonoids. By critically discussing their absorption barriers, enterohepatic circulation, and semi-synthetic strategies to enhance bioavailability, this work bridges the gap between rodent pharmacokinetics and their ultimate relevance to translational medicine.